Kellogg Eye Center publishes an inside look at Aravind Eye Care System's unique ability to provide cataract surgery for $120 per operation. The innovative hospital is on a mission to eliminate blindness in India.
A new study reveals previously unknown risk factors associated with an eye condition that causes serious progressive nearsightedness at a relatively young age. The findings, made through the largest-ever clinical study of the condition called keratoconus, could help more people receive newer treatments that can slow the problem and protect their vision.
An international team of scientists, that includes researchers from the University of Michigan, has identified 16 new genetic variations for age-related macular degeneration (AMD). Their findings nearly double the number of regions, or loci, associated with the disease.
When patients with glaucoma switched from a brand name drug to its generic counterpart, they were more likely to take their medication as directed compared to those who remained on the brand name drug, according to a new U-M Kellogg Eye Center study.
If all eye doctors prescribed the less expensive of two drugs to treat two common eye diseases of older adults, taxpayer-funded Medicare plans could save $18 billion over a 10-year period, say U-M researchers.
Retina surgeons at the University of Michigan Kellogg Eye Center have performed the first — and second -- surgeries in the United States to implant an artificial retina, or “bionic eye,” since the U.S. Food and Drug Administration approved the device last year.
The U-M Kellogg Eye Center will soon be one of just 13 U.S. locations offering a retinal implant - or "bionic eye" - that could provide partial sight for individuals with late-stage retinitis pigmentosa.
Richards is one of 10 recipients across the nation to win an award for Audacious Goals in Vision Research, a challenge sponsored by the National Eye Institute, part of the National Institutes of Health.
People who take statins to reduce their risk of cardiovascular disease are less likely to be diagnosed with the most common form of glaucoma, according to a nationwide study of more than 300,000 patients.
Researchers at the University of Michigan Kellogg Eye Center have identified a compound that could interrupt the chain of events that cause damage to the retina in diabetic retinopathy. The finding is significant because it could lead to a novel therapy that targets two mechanisms at the root of the disease: inflammation and the weakening of the blood barrier that protects the retina.
A team of cyclists is making Ann Arbor one of its stops on a cross-country trip to raise awareness of Graves' disease. On June 9, the U-M Kellogg Eye Center will host its third patient education workshop on Graves' disease and related thyroid disorders.
A new study published in the January issue of Ophthalmology reports that increased reliance on these newer technologies as a replacement for the more traditional visual field testing and fundus photography may undermine patient care.
The National Institutes of Health is supporting a new effort to understand the complications of diabetes. The University of Michigan will look at the cellular changes that contribute to vision loss, kidney failure and nerve damage in type 1 diabetics.
Drivers over age 65 are the fastest-growing segment of the driving population, and their eye care providers—ophthalmologists and optometrists—are playing an increasingly important role in assessing their ability to drive safely.
Many Americans suffer from diabetes and hypertension and, according to a study by researchers at the University of Michigan Kellogg Eye Center, these individuals may have an increased risk of developing open-angle glaucoma (OAG).
While it's generally known that African Americans have the highest risk for glaucoma (about 12 percent), a new study reports that Asian Americans also face a significant risk of developing glaucoma, a potentially blinding disease.
March Hoops to Beat Blindness (MHBB)—formerly March Madness Against Blindness—is back in its fifth year with a new name and a new cause: to support the University of Michigan's Kellogg Eye Center's research on treatments for Graves' eye disease, also known as thyroid eye disease (TED).